Pipeline

We are currently developing compounds in preclinical and clinical stages to slow down the progression and ultimately cure neurodegenerative diseases. For discovery research we collaborate closely with selected academic partners with strong and long-standing expertise in the field of neurodegenerative diseases and drug development.

TW001 (FNP122 for Ferrer) Oral Edaravone for ALS

Preclinical

Phase 1

Phase 2

Phase 3

The phase 3 study ADORE is owned and sponsored by Ferrer

TW101 Oral Edaravone for Alzheimer’s disease

Preclinical

Phase 1

Phase 2

Phase 3

TW301 for opthalmological indication

Preclinical

Phase 1

Phase 2

Phase 3

Combination treatment for Alzheimer’s disease

Preclinical

Phase 1

Phase 2

Phase 3

New targets for ALS

Preclinical

Phase 1

Phase 2

Phase 3

TW001 for ALS

TW001 is Treeway’s lead product with the active ingredient edaravone. Edaravone is a free radical scavenger targeting oxidative stress, a process known to play an important role in the pathogenesis of ALS. TW001 captures the harmful molecules that occur during this process and defuses them, slowing the progression of the disease. The compound is a patented patient-friendly oral formulation to be taken each day.

TW001, has been out licensed as FNP122 to Ferrer, a renowned international pharmaceutical company for certain territories including Europe. Treeway is committed to developing TW001 in the remaining territories.

TW001 was awarded Orphan Drug Designation status by the European Medicines Agency (EMA) in 2014 and by the Food and Drug Administration (FDA) in 2015.

ALS patients interested in participating in a clinical study with TW001 for ALS can find more information at www.tricals.org

ASURE STUDY: TW101 for Alzheimer’s disease

Treeway is presently exploring the potential of TW101AD in slowing down the progression of Alzheimer’s disease in patients. This study is kindly funded by the Alzheimer’s Drug Discovery Foundation (ADDF).

Treeway is presently preparing the phase 2a trial for TW101 under the name ASURE (Alzheimer’s Disease Study Using Oral Edaravone). ASURE explores the safety and effectiveness of an oral formulation of edaravone to delay disease progression in Alzheimer’s patients.

TW201

Treeway is investigating TW201 in its early-stage pipeline targeting ophthalmology indications with high unmet medical needs. TW201 represents new hope, potentially offering new options for patients with challenging eye conditions.

Discovery programs

Our discovery programs approach ALS from different angles which can be translated into three research lines:

Taking different approaches to discover effective treatments for ALS enhances the chances of success and enables the development of combination therapies that might be required to fully control the disease.

1

Biomarkers and genetics

To support the discovery programs, Treeway focuses on biomarkers and genetics as scientific topics that are crucial for drug development. For this purpose, Treeway collaborates with the ALS Center in Utrecht (UMC) and the Alzheimer Center of the Amsterdam UMC (VUMC) and Project Mine.

2

Motor neuron signaling

This discovery program focuses on the earliest deficiencies in the motor neuron physiology which might also be caused by non-cell-autonomous factors.

3

The immune system

This research lines explores approaches to shifting the balance of the immune response from the pro-inflammatory response back towards its protective function.